Corinne Hoesli and Cellterix Biomedical Inc. Receive the Deploy Award
February 12, 2026 – News from Our Researchers
Professor Corinne Hoesli and Cellterix Biomedical Inc. have received the prestigious Deployment Award, presented by Desjardins in partnership with the McGill Innovation Fund, to support the development of an innovative cell therapy approach for type 1 diabetes.
This support will help accelerate Cellterix’s efforts to make cell therapy more accessible to people living with diabetes, notably by strengthening intellectual property, advancing key preclinical efficacy studies, and reinforcing the company’s positioning with potential commercial partners.
Prof. Hoesli also leads one of the structuring activities funded by Médicament Québec, focused on scaling up the biofabrication of therapeutic organoids derived from stem cells. This initiative contributes to building sustainable biofabrication capacities in Québec by strengthening the infrastructure and expertise required to develop and transfer innovative therapies to industry.
Médicament Québec congratulates Prof. Hoesli and her team on this recognition and underscores the importance of supporting initiatives that consolidate the platforms and know-how essential to Québec’s drug development ecosystem.
Comments are closed.